The ACT4 ALS-MND centers

CHU d'Angers

Pr Julien Cassereau : Responsable du Centre SLA

SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

4 rue Larrey
49933 Angers
France

CHU de Bordeaux

Pr Gwendal Le-Masson : Responsable du Centre SLA

SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

Hôpital Pellegrin
Place Amélie-Raba Léon
33000 Bordeaux
France

CHU de Brest

Dr Steeve Genestet : Responsable du Centre SLA

Hôpital de la Cavale Blanche
Boulevard Tanguy Prigent
29200 Brest
France

CHU de Caen

Dr Mathilde Lefilliatre : Responsable du Centre SLA

Hôpital Côte de Nacre
Avenue de la Côte de Nacre
14033 Caen Cedex 9
France

CHU de Clermont-Ferrand

Dr Nathalie Guy : Responsable du Centre SLA

SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS (Completed)
TRIALS // Treatment Combining Riluzole and IFB-088 in Bulbar ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

Site Gabriel-Montpied
58 rue Montalembert
63000 Clermont-Ferrand
France

CHU de Dijon

Dr Agnès Jacquin-Piques : Responsable du Centre SLA

Hôpital François Mitterrand
2 bd Maréchal de Lattre de Tassigny
21000 Dijon
France

CHU de la Réunion

Dr Ariane Choumert : Responsable du Centre SLA

FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

site Sud
97448 Saint Pierre cedex
France

CHU de Limoges

Pr Philippe Couratier : Responsable du Centre SLA Limoges Coordonnateur du réseau ACT4ALS-MND Coordonnateur de la Filière de Santé FilSLAN

ASTRALS // A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
DAZALS // Dazucorilant in Patients With ALS (Active not recruiting)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
ADORE // Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With ALS (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
FG-CoALS // Franco-German cohort study to determine factors associated with weight loss in amyotrophic lateral sclerosis (Recruiting)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

2 Av. Martin Luther King
87000 LIMOGES
France

CHU de Lyon

Dr Emilien Bernard : responsable du Centre SLA

ASTRALS // A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
DAZALS // Dazucorilant in Patients With ALS (Active not recruiting)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS (Completed)
TRIALS // Treatment Combining Riluzole and IFB-088 in Bulbar ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

59 boulevard Pinel
69677 Lyon-Bron cedex
France

CHU de Marseille

Dr Aude-Marie Grapperon : Responsable du Centre SLA

ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
DAZALS // Dazucorilant in Patients With ALS (Active not recruiting)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
TRIALS // Treatment Combining Riluzole and IFB-088 in Bulbar ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
ADORE // Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With ALS (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
FG-CoALS // Franco-German cohort study to determine factors associated with weight loss in amyotrophic lateral sclerosis (Recruiting)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

Hôpital de la Timone
264 rue Saint-Pierre
13005 Marseille
France